Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (AU2004311869) Compositions and methods to treat recurrent medical conditions
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique
CLAIMS
We claim:
1. A method for alleviating a recurrent medical affliction in a subject which comprises administering to the subject a therapeutically effective amount of:
(i) at least one first pharmacologic agent, or pharmaceutically acceptable salt thereof, that enhances learning; and
(ii) at least one second pharmacologic agent, or pharmaceutically acceptable salt thereof, that alleviates said recurrent medical affliction;
wherein said first phannacologic agent is administered on an acute basis.
2.           The method of claim 1, wherein said method of administering said first pharmacologic agent in combination with said second pharmacologic agent alleviates said recurrent medical affliction in a subject more effectively than administering said second pharmacologic agent alone.
3.           The method of claim 1, wherein said first pharmacologic agent is an NMDA partial receptor agonist.
4.          The method of claim 1, wherein said first pharmacologic agent comprises DCS or pharmaceutically acceptable salt thereof.
5.          The method of claim 4, wherein said DCS or pharmaceutically acceptable salt thereof is administered at a dose of between about 0.25 mg/kg and 10 mg/kg body weight of the subject.
6.          The method of claim 4, wherein a B-complex vitamin is co-administered with said DCS or pharmaceutically acceptable salt thereof.
7.          The method of claim 4, wherein said recurrent medical affliction is erectile
dysfunction. 
8. The method of claim 7, wherein said second pharmacologic agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of sildenafil, tadalafil, and vardenafil.
9. The method of claim 4, wherein said recurrent medical affliction is female sexual dysfunction.
10. The method of claim 9, wherein said second pharmacologic agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of sildenafil, tadalafil, vardenafil, PT-141, bupropion, and apomorphine.
11. The method of claim 4, wherein said recurrent medical affliction is insomnia.
12. The method of claim 11, wherein second pharmacologic agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of eszopiclone, indiplon, zaleplon, zopiclone, zolpidem, lorazepam, clonazepam, oxazepam, flurazepam, triazolam, temazepam, and alprazolam.
13.        The method of claim 4, wherein said second pharmacologic agent or pharmaceutically acceptable salt thereof is administered with a frequency greater than or equal to once per day, and wherein said second pharmacologic agent or pharmaceutically acceptable salt thereof is administered for a duration of greater than or equal to four days.
14.        The method of claim 13, wherein said recurrent medical affliction is selected from the group consisting of chronic pain and neuropathic pain.
15.        The method of claim 14, wherein said second pharmacologic agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of pregabalin, gabapentin, nortriptyline, and amitriptyline.
16. The method of claim 13 wherein said recurrent medical affliction is insomnia.
17. The method of claim 16, wherein said second pharmacologic agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of eszopiclone, indiplon, zaleplon, zopiclone, and zolpidem.
18. The method of claim 13, wherein said recurrent medical affliction is attention deficit-hyperactivity disorder.
19. The method of claim 18, wherein said second pharmacologic agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of methylphenidate, atomoxetine, amphetamine, and dextroamphetamine.
20.        The method of claim 13, wherein said recurrent medical affliction is depression.
21.        The method of claim 20, wherein said second pharmacologic agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of desipramine, amitriptyline, nortriptyline, fluoxetine, paroxetine, sertraline, fluvoxamine, and citalopram.
22.        The method of claim 13, wherein said recurrent medical affliction is female sexual dysfunction.
23.        The method of claim 22, wherein second pharmacologic agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of bupropion, testosterone, and estradiol.
24.        A pharmaceutical kit comprising separate dosage units arranged for successive once-daily administration to subjects comprising: (i) between 2 and 20 first dosage units, wherein said first dosage units comprise: a. a pharmaceutical acceptable carrier;
b. at least one first pharmacologic agent, or pharmaceutically acceptable salt thereof, that enhances learning;
c. a therapeutically effective amount of a second pharmacologic agent, or pharmaceutically acceptable salt thereof, that alleviates a recurrent medical affliction;
(ii) between 4 and 90 second dosage units, wherein said second dosage units comprise:
a. a pharmaceutically acceptable carrier; and
b. a therapeutically effective amount of a second pharmacologic agent, or pharmaceutically acceptable salt thereof, that alleviates a recurrent medical affliction;
wherein each first dosage unit is separated from additional first dosage units by at least three second dosage units; and wherein said second dosage units do not contain said first pharmacologic agent.
25.         The pharmaceutical kit of claim 24, wherein said first pharmacologic agent is DCS, or pharmaceutically acceptable salt thereof, and wherein the therapeutically effective amount of DCS is between about 25 mg and 500 mg.
26.        The pharmaceutical kit of Claim 24, wherein said first dosage units and said second dosage units are administered orally.
27.        A pharmaceutical composition useful for alleviating a recurrent medical affliction in a subject comprising:
(i) a first pharmacologic agent, or pharmaceutically acceptable salt thereof, that enhances learning;
(ii) a second pharmacologic agent, or pharmaceutically acceptable salt thereof, that alleviates said recurrent medical affliction; and
(iii) a pharmaceutically acceptable carrier.
28.        The pharmaceutical composition of claim 27, wherein said recurrent medical affliction is selected from the group consisting of female sexual dysfunction and male erectile dysfunction, and wherein said first pharmacologic agent, or pharmaceutically acceptable salt thereof, comprises DCS.
29.         The pharmaceutical composition of claim 28, wherein said second pharmacological agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of sildenafil, tadalafil, PT-141, apomorphine, testosterone, bupropion, estradiol, and vardenafil.
30.        The pharmaceutical composition of claim 27, wherein said recurrent medical affliction is selected from the group consisting of chronic pain and neuropathic pain, and wherein said first pharmacologic agent, or pharmaceutically acceptable salt thereof, comprises DCS.
31.        The pharmaceutical composition of claim 30, wherein said second pharmacologic agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of pregabalin, gabapentin, nortriptyline, and amitriptyline.
32.        The pharmaceutical composition of claim 27 wherein said recurrent medical affliction is insomnia, and wherein said first pharmacologic agent, or pharmaceutically acceptable salt thereof, comprises DCS.
33.        The pharmaceutical composition of claim 30, wherein said second pharmacologic agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of eszopiclone, indiplon, zaleplon, zopiclone, zolpidem, lorazepam, clonazepam, oxazepam, flurazepam, triazolam, temazepam, and alprazolam.
34.        The pharmaceutical composition of claim 27, wherein said recurrent medical affliction is attention deficit-hyperactivity disorder, and wherein said first pharmacologic agent, or pharmaceutically acceptable salt thereof, comprises DCS.
35.        The pharmaceutical composition of claim 34, wherein said second pharmacologic agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of methylphenidate, atomoxetine, amphetamine, and dextroamphetamine.
36.        The pharmaceutical composition of claim 27, wherein said recurrent medical affliction is depression, and wherein said first pharmacologic agent, or pharmaceutically acceptable salt thereof, comprises DCS.
37.        The pharmaceutical composition of claim 36, wherein said second pharmacologic agent or pharmaceutically acceptable salt thereof comprises a pharmacologic agent or pharmaceutically acceptable salt thereof selected from the group consisting of desipramine, amitriptyline, nortriptyline, fluoxetine, paroxetine, sertraline, fluvoxamine, and citalopram.
38.        The pharmaceutical composition of claim 27, wherein said first pharmacologic agent, or pharmaceutically acceptable salt thereof, comprises DCS; and wherein said pharmaceutical composition further comprises a B-complex vitamin.